Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597209 | 0.89 | L3MBTL1 (0.63) | L3MBTL1GAAKMT2AMEN1CYP3A4 | |
| SCHEMBL7465795 | 0.83 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1GAABRD4KMT2A | |
| SCHEMBL7466727 | 0.83 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1GAABRD4KMT2A | |
| SCHEMBL7460760 | 0.80 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1GAABRD4KMT2A | |
| SCHEMBL7476036 | 0.80 | ALDH1A1 (0.67) | L3MBTL1ALDH1A1GAABRD4KMT2A | |
| SCHEMBL5670577 | 0.79 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL20414554 | 0.74 | L3MBTL1 (0.63) | L3MBTL1GAAKMT2AMEN1CYP3A4 | |
| SCHEMBL7476434 | 0.74 | L3MBTL1 (0.63) | L3MBTL1GAAKMT2AMEN1CYP3A4 | |
| SCHEMBL18209180 | 0.74 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL17055837 | 0.74 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | L3MBTL1 1176/4885ALDH1A1 1904/4885GAA 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.